Effects of Angiotensin Receptor Blockers on Ambulatory Plasma Renin Activity in Healthy, Normal Subjects During Unrestricted Sodium Intake

American Journal of Hypertension

Volumn 20, Issue 8, 2007, Pages 907-916

  Jones, Michael R ^a   Sealey, Jean E ^b   Laragh, John H ^b  

^a DAIICHI SANKYO INC   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Angiotensin receptor blocker; irbesartan; olmesartan medoxomil; PRA; renin angiotensin system; valsartan

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BIOCHEMICAL MARKER; IRBESARTAN; OLMESARTAN; PLACEBO; VALSARTAN;

ADULT; ALDOSTERONE URINE LEVEL; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG INDUCED HEADACHE; FEMALE; HUMAN; MALE; NORMAL HUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM INTAKE;

ADOLESCENT; ADULT; AGED; ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIOLOGICAL MARKERS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PROGNOSIS; RADIOIMMUNOASSAY; REFERENCE VALUES; RENIN; RENIN-ANGIOTENSIN SYSTEM; SINGLE-BLIND METHOD; SODIUM CHLORIDE, DIETARY; TETRAZOLES; VALINE;

EID: 34547454237     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2007.04.009     Document Type: Article

References (27)

1. McConnaughey M.M., McConnaughey J.S., and Ingenito A.J. Practical considerations of the pharmacology of angiotensin receptor blockers. J Clin Pharmacol 39 (1999) 547-559
2. Mizuno M., Sada T., Ikeda M., Fukuda N., Miyamoto M., Yanagisawa H., and Koike H. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 285 (1995) 181-188
3. Azizi M., Chatellier G., Guyene T.T., Murieta-Geoffroy D., and Menard J. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 92 (1995) 825-834
4. Azizi M., Guyene T.T., Chatellier G., Wargon M., and Menard J. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 29 (1997) 634-640
5. Mazzolai L., Maillard M., Rossat J., Nussberger J., Brunner H.R., and Burnier M. Angiotensin II receptor blockade in normotensive subjects: a direct comparison of three AT1 receptor antagonists. Hypertension 33 (1999) 850-855
6. Azizi M., Linhart A., Alexander J., Goldberg A., Menten J., Sweet C., and Menard J. Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients. J Hypertens 18 (2000) 1139-1147
7. Belz G.G., Butzer R., Kober S., and Mutschler E. Pharmacodynamic studies on the angiotensin II type 1 antagonists irbesartan and candesartan based on angiotensin II dose response in humans. J Cardiovasc Pharmacol 39 (2002) 561-568
8. Maillard M.P., Wurzner G., Nussberger J., Centeno C., Burnier M., and Brunner H.R. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Clin Pharmacol Ther 71 (2002) 68-76
9. Azizi M., Bissery A., Bura-Riviere A., and Menard J. Dual renin-angiotensin system blockade restores blood pressure-renin dependency in individuals with low renin concentrations. J Hypertens 21 (2003) 1887-1895
10. Azizi M., Menard J., Bissery A., Guyenne T.T., Bura-Riviere A., Vaidyanathan S., and Camisasca R.P. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 15 (2004) 3126-3133
11. Azizi M., Bissery A., Lamarre-Cliche M., and Menard J. Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans. Hypertension 43 (2004) 785-790
12. Resnick L.M., Catanzaro D., Sealey J.E., and Laragh J.H. Acute vascular effects of the angiotensin II receptor antagonist olmesartan in normal subjects: relation to the renin-aldosterone system. Am J Hypertens 17 (2004) 203-208
13. Hasler C., Nussberger J., Maillard M., Forclaz A., Brunner H.R., and Burnier M. Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor. Clin Pharmacol Ther 78 (2005) 501-507
14. Guyene T.T., Bellet M., Sassano P., Serrurier D., Corvol P., and Menard J. Crossover design for the dose determination of an angiotensin converting enzyme inhibitor in hypertension. J Hypertens 7 (1989) 1005-1012
15. Massien C., Azizi M., Guyene T.T., Vesterqvist O., Mangold B., and Menard J. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans. Clin Pharmacol Ther 65 (1999) 448-459
16. Menard J., Guyene T.T., Chatellier G., Kleinbloesem C.H., and Bernadet P. Renin release regulation during acute renin inhibition in normal volunteers. Hypertension 18 (1991) 257-265
17. Sealey J.E. Plasma renin activity and plasma prorenin assays. Clin Chem 37 (1991) 1811-1819
18. Benicar (Olmesartan Medoxomil) Prescribing Information (2004), Sankyo Pharma, Inc, Parsippany, NJ
19. Diovan (Valsartan) Prescribing Information (2005), Novartis Pharmaceuticals, East Hanover, NJ
20. Avapro (Irbesartan) Prescribing Information (2005), Bristol-Myers Squibb Sanofi-Aventis Partnership, New York, NY
21. Mire D.E., Silfani T.N., and Pugsley M.K. A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J Cardiovasc Pharmacol 46 (2005) 585-593
22. Case D.B., Wallace J.M., Keim H.J., Weber M.A., Drayer J.I., White R.P., Sealey J.E., and Laragh J.H. Estimating renin participation in hypertension: superiority of converting enzyme inhibitor over saralasin. Am J Med 61 (1976) 790-796
23. Case D.B., Wallace J.M., Keim H.J., Weber M.A., Sealey J.E., and Laragh J.H. Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme. N Engl J Med 296 (1977) 641-646
24. Ferrari P., Shaw S.G., Nicod J., Saner E., and Nussberger J. Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism. J Hypertens 22 (2004) 377-381
25. James G.D., Sealey J.E., Muller F., Alderman M., Madhavan S., and Laragh J.H. Renin relationship to sex, race and age in a normotensive population. J Hypertens 4 Suppl (1986) S387-S389
26. He J., Klag M.J., Appel L.J., Charleston J., and Whelton P.K. The renin-angiotensin system and blood pressure: differences between blacks and whites. Am J Hypertens 12 (1999) 555-562
27. Gordon R.D., Wolfe L.K., Island D.P., and Liddle G.W. A diurnal rhythm in plasma renin activity in man. J Clin Invest 45 (1966) 1587-1592